Prognostic Value of Iron-Homeostasis Regulating Peptide Hepcidin in Coronary Heart Disease-Evidence from the Large AtheroGene Study

被引：23

作者：

Zeller, Tanja ^{[1
,2
]}

Altay, Alev ^{[1
]}

Waldeyer, Christoph ^{[1
]}

Appelbaum, Sebastian ^{[1
]}

Ojeda, Francisco ^{[1
]}

Ruhe, Julia ^{[1
]}

Schnabel, Renate B. ^{[1
,2
]}

Lackner, Karl J. ^{[3
,4
]}

Blankenberg, Stefan ^{[1
,2
]}

Karakas, Mahir ^{[1
,2
]}

机构：

[1] Univ Heart Ctr Hamburg, Dept Gen & Intervent Cardiol, D-20246 Hamburg, Germany

[2] German Ctr Cardiovasc Res DZHK, Partner Site Hamburg, D-20246 Hamburg, Germany

[3] German Ctr Cardiovasc Res DZHK, Partner Site Rhein Main, D-55131 Mainz, Germany

[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Lab Med, D-55131 Mainz, Germany

来源：

BIOMOLECULES | 2018年 / 8卷 / 03期

关键词：

hepcidin; iron; coronary heart disease; biomarker; prognosis; DEFICIENCY; RISK;

D O I：

10.3390/biom8030043

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Iron is essential in terms of oxygen utilization and mitochondrial function. The liver-derived peptide hepcidin has been recognized as a key regulator of iron homeostasis. Since iron metabolism is crucially linked to cardiovascular health, and low hepcidin was proposed as potential new marker of iron metabolism, we aimed to evaluate the prognostic value of hepcidin in a large cohort of patients with coronary heart disease (CHD). Serum levels of hepcidin were determined at baseline in patients with angiographically documented CHD. The main outcome measure was non-fatal myocardial infarction (MI) or cardiovascular death. During a median follow-up of 4.1 years, 10.3% experienced an endpoint. In Cox regression analyses for hepcidin the hazard ratio for future cardiovascular death or MI was 1.03 (95% confidence interval (CI) 0.91-1.18, p = 0.63) after adjustment for sex and age. This association virtually did not change after additional adjustment for body mass index (BMI), smoking status, hypertension, diabetes, dyslipidemia, and surrogates of cardiac function (NT-proBNP), size of myocardial necrosis (troponin I), and anemia (hemoglobin). In this study, by far the largest evaluating the predictive value of hepcidin, hepcidin levels were not associated with future MI or cardiovascular death. This implicates a limited, if any, role for hepcidin in secondary cardiovascular risk prediction.

引用

页数：7

共 22 条

[1]

Galy B., Ferring-Appel D., Sauer S.W., Kaden S., Lyoumi S., Puy H., Kolker S., Grone H.J., Hentze M.W., Iron regulatory proteins secure mitochondrial iron sufficiency and function, Cell Metab, 12, pp. 194-201, (2010)

[2]

Von Haehling S., Jankowska E.A., Van Veldhuisen D.J., Ponikswski P., Anker S.D., Iron deficiency and cardiovascular disease, Nat. Rev. Cardiol, 12, pp. 659-669, (2015)

[3]

Anker S.D., Comin Colet J., Filippatos G., Willenheimer R., Dickstein K., Drexler H., Luscher T.F., Bart B., Banasiak W., Niegowska J., Et al., Ferric carboxymaltose in patients with heart failure and iron deficiency, N. Engl. J. Med, 361, pp. 2436-2448, (2009)

[4]

Florian A., Ludwig A., Rosch S., Ylidiz H., Klumpp S., Sechtem U., Yilmaz A., Positive effect of intravenous iron-oxide administration on left ventricular remodelling in patients with acute ST-elevation myocardial infarction—A cardiovascular magnetic resonance (CMR) study, Int. J. Cardiol, 73, pp. 184-189, (2014)

[5]

Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J., Falk V., Gonzalez-Juanatey J.R., Harjola V.P., Jankowska E.A., Et al., Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure, Eur. Heart J, 18, pp. 891-975, (2016)

[6]

Zhao N., Zhang A.S., Enns C.A., Iron regulation by hepcidin, J. Clin. Investig, 123, pp. 2337-2343, (2013)

[7]

Nemeth E., Tuttle M.S., Powelson J., Vaughn M.D., Donovan A., Ward D.M., Ganz T., Kaplan J., Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization, Science, 306, pp. 2090-2093, (2004)

[8]

Jankowska E.A., Malyszko J., Ardehali H., Koc-Zorawska E., Banasiak W., Von Haehling S., Macdougall I.C., Weiss G., McMurray J.J., Anker S.D., Et al., Iron status in patients with chronic heart failure, Eur. Heart J, 34, pp. 827-834, (2013)

[9]

Zacharski L.R., Shamayeva G., Chow B.K., Depalma R.G., Ferritin and percent transferrin saturation levels predict type 2 diabetes risk and cardiovascular disease outcomes, Curr. Diabetes Rev, 13, pp. 428-436, (2017)

[10]

Depalma R.G., Hayes V.W., Chow B.K., Shamayeva G., May P.E., Zacharski L.R., Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: A substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial, J. Vasc. Surg, 51, pp. 1498-1503, (2010)

← 1 2 3 →